Objective Grading of MTS With LSCI and Thermography
MTS LSCI
Is Objective Grading of Mesenteric Traction Syndrome With Laser Speckle Contrast Imaging Interchangeable With Digital Thermography
1 other identifier
observational
98
1 country
1
Brief Summary
Mesenteric traction syndrome (MTS) is defined as hypotension, tachycardia and facial flushing in the first hour of surgery, caused by mesenteric traction/abdominal exploration. MTS occurs frequently during abdominal surgery, with incidence around 80 % during open surgery, and lower during minimally invasive surgery. MTS can be divided into different severities using the degree of facial flushing, with the most severe level of MTS being associated with increased postoperative morbidity. Today MTS is diagnosed and graded subjectively by the surgical team, with marked difficulty and limitations. Therefore the investigators developed a cut-off value using the Laser Speckle Contrast Imaging (LSCI), which the investigators wish to confirm in a new cohort, while also examining whether LSCI is interchangeable with digital thermography, which is simpler and cheaper to perfom. The investigators will measure facial perfusion during the first hour of surgery and take blood samples at predefined timepoints to use for biochemical verification of the different severities of MTS. Three cohorts we planned to include 45 open esophagectomies or gastrectomies 50 whipple surgery 20 robot assisted esophagectomies or gastrectomies These patients will be use in multiple articles examining different aspects of MTS One study examining LSCI and thermography for the identification and grading of MTS will use 60 patients undergoing open esophagectomy or gastrectomy or whipple surgery, in this study patients will not be excluded if they are found to be disseminated. However we ended up including 37 open esophagectomies - due to few patients undergoing open esophagectomy, this were included over a time period of almost 2,5 years 50 whipple 11 Robotic esophagectomies - due to LSCI being impossible to use on robotic esophagectomies and thermography being diffciult to fit on these patients and as such not being feasible
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2021
CompletedFirst Posted
Study publicly available on registry
March 15, 2021
CompletedStudy Start
First participant enrolled
March 16, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 23, 2027
ExpectedApril 6, 2025
April 1, 2025
2.3 years
March 8, 2021
April 2, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Severity of MTS - measured facial perfusion
Facial perfusion measured with LSCI and Digital Thermography
first hour of surgery
Secondary Outcomes (10)
Biochemical markers of MTS - prostacyclin
During surgery
Hemodynamics
During surgery
Markers of postoperative impact of MTS - IL6 and endothelial damage markers
During and after surgery
30-day postoperative morbidity
30 days post surgery
Incidence of objective MTS during whipples procedure with methylprednisolone prophylaxis
During surgery
- +5 more secondary outcomes
Eligibility Criteria
3 cohorts * open esophagectomies * robotic assisted esophagectomies * whipples procedure
You may qualify if:
- Undergoing curative surgery for esopageal, gastric, doudenal or pancreatic cancer
You may not qualify if:
- Known flushing disease
- Patients recieving NSAID and corticosteroid presurgery, Whipple is allowed to recieve single dose of 125 mg Methylprednisone as part of the standard of care at our facility.
- Palliative surgery
- Surgery not completed due to disseminated disease - patients will still be used in examination of LSCI and Thermography analysis even if desiminated
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rigshospitalet
København Ø, Capital Region, 2100, Denmark
Study Officials
- PRINCIPAL INVESTIGATOR
August Olsen
Rigshospitalet, Denmark
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD PhD student
Study Record Dates
First Submitted
March 8, 2021
First Posted
March 15, 2021
Study Start
March 16, 2021
Primary Completion
June 30, 2023
Study Completion (Estimated)
August 23, 2027
Last Updated
April 6, 2025
Record last verified: 2025-04